Cardiac Arrest With Successful Resuscitation Clinical Trial
Official title:
Proteomic Profiling to Reveal Novel Prognostic Markers for Neurological Outcome Following Resuscitation
Background: Cardiac arrest is a life-threatening event. Intensivists are challenged with an
increasing number of patients with uncertain neurological outcome following cardiopulmonary
resuscitation (CPR). The prognostic value of current biomarkers for neurophysiologic
long-term outcome is limited.
Hypothesis: We hypothesize that specific brain-derived tissue leakage proteins can be
identified to reveal novel, more reliable prognostic biomarkers for good neurological
outcome.
Methods: This translational study (n=100) is a combination of a prospective basic science
study intended to reduce the number of potential plasma biomarker candidates by proteomic
shotgun analyses in brain tissue autopsy samples and plasma samples from resuscitated
patients (n=10) and a prospective clinical validation study in a large study population
(n=90) by high-throughput analyses. Selection of proteomic markers and signature estimation
will be performed to discriminate patients with good and poor outcome.
Clinical perspective: A structured proteomic analysis approach might identify the best marker
out of all proteins liberated during cellular damage.
Background: Cardiac arrest is a life-threatening event. Intensivists are challenged with an
increasing number of patients with uncertain neurological outcome following cardiopulmonary
resuscitation (CPR). The prognostic value of current biomarkers for neurophysiologic
long-term outcome is limited. Therefore, identification of novel plasma markers with higher
predictive value for neurophysiological recovery is critical for patient management after
CPR.
Hypothesis: We hypothesize that specific brain-derived tissue leakage proteins can be
identified to reveal novel, more reliable prognostic biomarkers for good neurological
outcome.
Methods: This translational study (n=100) is a combination of a prospective basic science
study intended to reduce the number of potential plasma biomarker candidates by proteomic
shotgun analyses in brain tissue autopsy samples and plasma samples from resuscitated
patients (n=10) and a prospective clinical validation study in a large study population
(n=90) by high-throughput analyses. Samples will be analyzed by proteomic shotgun analyses
using the Q-Exactive quadrupole-orbitrap mass spectrometer (MS). MS/MS data will be
interpreted by the MaxQuant and Perseus Software. In order to identify brain-derived proteins
within plasma, the plasma proteome of 10 resuscitated patients will be compared to the
proteomic profile of brain tissue. This will reduce the number of potential plasma biomarker
candidates associated with neurologic outcome. The prospective validation in plasma samples
will be performed by a targeted proteomics approach using selected reaction monitoring (SRM)
on a triple quadrupole ion MS. Neurological outcome will be assessed by the five-point scale
(death, persistent vegetative state, severe disability, moderate disability, and good
recovery) according to the cerebral performance categories (CPC). A CPC sore of <3 is
considered a good neurological outcome. Selection of proteomic markers and signature
estimation will be performed by L1 regularized logistic regression, where the tuning
parameter will be optimized by cross-validated model performance. The signature's ability to
discriminate patients with good and poor outcome will be described by ROC analysis.
Clinical perspective: An accurate predictor of neurological outcome following CPR is of
utmost clinical importance. However, previous studies focused on a very limited array of
biomarkers. Therefore, a structured proteomic analysis approach might identify the best
marker out of all proteins liberated during cellular damage.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04114773 -
Rehabilitation for Survivors of Cardiac Arrest Focused on Fatigue
|
N/A | |
Completed |
NCT04624776 -
Steroid Treatment After Resuscitated Out-of-Hospital Cardiac Arrest
|
Phase 2 | |
Completed |
NCT01719770 -
Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac Arrest
|
Phase 3 | |
Recruiting |
NCT05482945 -
CardioPulmonary Resuscitation With Argon (CPAr) Trial
|
N/A | |
Completed |
NCT03112486 -
Out-of-hospital Cardiac Arrest (OHCA) Biomarkers
|
||
Recruiting |
NCT05386199 -
The Role of Serotonin in Intensive Care Patients
|
||
Completed |
NCT03889340 -
Study of Brain Cools Device in Patients Resuscitated From Cardiac Arrest
|
||
Recruiting |
NCT03841708 -
Hemodynamic Optimization Through Pleth Variability Index for OHCA
|
N/A | |
Completed |
NCT03908346 -
A Novel Patient Decision Aid for Surrogate Decision Makers of Comatose Survivors of Cardiac Arrest
|
N/A | |
Completed |
NCT02998749 -
Gasping Improves Long-term Survival After Out-of-hospital Cardiac Arrest
|
N/A | |
Not yet recruiting |
NCT06466980 -
Ventilator - Associated Event After Cardiac Arrest
|
||
Withdrawn |
NCT05000320 -
VIGAB-BIOSTAT: Neuronal Injury Panel Substudy
|
||
Recruiting |
NCT05090930 -
Innovative Technologies for the Treatment of Pulmonary and Heart Failure
|
N/A | |
Recruiting |
NCT05564754 -
Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation
|
N/A | |
Recruiting |
NCT06207942 -
Stepcare Extended Follow-up Substudy
|
N/A |